Skip to main content
GENB logo

Generate Biomedicines, Inc.

GENBNASDAQHealthcareBiotechnology

$15.38Today:- (-)

As of Oct 28, 2026 close

Market cap
$1.97B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$11.00$22.67
Volume (live)
-
Avg. volume (3M)
1.13M

Generate Biomedicines (GENB) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Generate Biomedicines used $200.62M of cash in operating activities and spent $3.51M on capital expenditures. That left free cash flow of −$204.13M.

Generate Biomedicines Cash Flow Statement Analysis

Values in millions USD

Income StatementBalance SheetCash FlowRatios
Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Generate Biomedicines, Inc. (GENB) - Annual data in millions USD
BreakdownFY 2025FY 2024
Period endingDec 2025Dec 2024
Operating Activities
Net Income-222.97-181.38
Depreciation & Amortization13.1815.35
Stock Based Compensation20.5819.47
Change in Working Capital-14.6228.12
Change in Accounts Receivable0.31-0.21
Change in Accounts Payable-2.133.50
Change in Other Working Capital1.7324.83
Other Operating Activities3.210.70
Net Cash from Operating Activities-200.62-117.75
Investing Activities
Capital Expenditures-3.51-3.45
Purchases of Investments-164.73-282.98
Sales/Maturities of Investments285.01228.69
Other Investing Activities0.000.01
Net Cash from Investing Activities116.77-57.73
Financing Activities
Debt Repayment-8.16-11.12
Common Stock Issued1.100.00
Other Financing Activities13.12102.45
Net Cash from Financing Activities28.0691.33
Summary
Net Change in Cash-55.79-84.15
Cash at Beginning of Period181.83265.98
Cash at End of Period126.04181.83
Free Cash Flow-204.13-121.20

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Generate Biomedicines Cash Flow

What is Generate Biomedicines's free cash flow?

Generate Biomedicines had negative free cash flow of $204.13M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$200.62M minus $3.51M of capital expenditures.

How much does Generate Biomedicines spend on capital expenditures?

Generate Biomedicines spent $3.51M on capital expenditures in fiscal 2025, compared with $3.45M a year earlier.

Does Generate Biomedicines pay dividends or buy back shares?

Generate Biomedicines's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition